Phase II study of Neoadjuvant ArOMatase Inhibitor therapy for ER+ breast cancer (NAOMI)
NCT04568616
This study will identify changes in tumor metabolic markers in post-menopausal patients with ER+/HER2- breast cancer treated with neoadjuvant letrozole, and identify factors predictive of patient adherence to adjuvant endocrine therapy.